The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Apr. 11, 2006
Filed:
Oct. 18, 2002
David Young, Ellicott City, MD (US);
Sian E. Bigora, Gambrills, MD (US);
Leonid V. Gibiansky, North Potomac, MD (US);
William R. Gillespie, Apex, NC (US);
Theresa A. Shepard, Burnham, GB;
Colm B. Farrell, Marlow, GB;
David Young, Ellicott City, MD (US);
Sian E. Bigora, Gambrills, MD (US);
Leonid V. Gibiansky, North Potomac, MD (US);
William R. Gillespie, Apex, NC (US);
Theresa A. Shepard, Burnham, GB;
Colm B. Farrell, Marlow, GB;
Globomax LLC, Hanover, MD (US);
Abstract
A biological modeling system and method for enhanced computer-aided analysis of biological response data provides information synthesized from immediate and extended release in vivo data and in vitro data. An executable model of a biological system is developed from information and structures based on the data. In a preferred embodiment, a two stage approach to modeling is used in the development of an IVIVC. The first stage of the procedure is deconvolution, where the percentage of drug absorbed is determined. In the second stage, the in vivo percentage absorbed data is correlated to the in vitro fraction or percentage dissolved data. This correlation then represents a point-to-point relationship between the in vitro dissolution and the in vivo input rate of the drug from the dosage form. In such a correlation, the in vitro dissolution and in vivo absorption profiles are either directly superimposable or may be made to be superimposable by the use of a scaling factor. Prior to the deconvolution stage, a unit impulse response function can be determined from immediate-release concentration-time data. This impulse response function is used in the deconvolution process to determine the in vivo percent absorbed for the extended release formulations. A nonlinear IVIVC model is developed that can incorporate time-scaling and time-shifting into the model if needed. After the two-stage modeling is completed, the predictability of the developed IVIVC model is evaluated by both internal and external validation.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile